Artgen Biotech (MOEX: ABIO), a biotechnology company with a portfolio of innovative drugs and treatment methods for more effective fight against human diseases, has published its operating results for the 9 months of 2025, prepared in accordance with Russian Accounting Standards (RAS).
Following its updated development strategy for 2024-2026, Artgen Biotech completed the process of separating its businesses into separate legal entities by the beginning of 2025 and now generates revenue solely from dividends of its subsidiaries.
The Company's RAS revenue for 9M 2025 grew by 153% compared to the same period of the previous year and amounted to RUB 290.468 million. Net profit increased by 21% to RUB 266.388 million.
Key Indicators of P&L Statement for 9M 2025
|
RUB, thousands |
January – September 2025 |
January – September 2024 |
% change |
|
Revenue |
290 468 |
114 895 |
152,8% |
|
Cost of sales |
(10 618) |
(52 317) |
-79,7% |
|
Gross profit (loss) |
279 850 |
62 578 |
347,2% |
|
Commercial expenses |
- |
(11 926) |
-100% |
|
Management expenses |
(82 688) |
(70 397) |
17,5% |
|
Profit (loss) from sales |
197 162 |
(19 745) |
1098,5% |
|
Income from participation in other entities |
- |
253 634 |
-100% |
|
Interest receivable |
54 436 |
47 259 |
15,2% |
|
Interest payable |
(30 162) |
(26 468) |
14% |
|
Other income (expenses), net |
31 945 |
(33 373) |
195,7% |
|
Net profit (loss) |
266 388 |
220 722 |
20,7% |
|
Net profit, % |
91,70% |
192,1% |
- |
Artgen Biotech is a biotechnology company with a portfolio of innovative platform R&D projects, bringing them into practical healthcare. The Artgen Biotech Group comprises companies at various stages of development — from the seed stage to early growth and maturity — as well as companies that form an ecosystem for accelerating biotech R&D within the Group.
The unaudited non-consolidated RAS financial statements of Artgen PJSC for 9M 2025 are available on the Company's corporate website in the "Investors" section (RAS Financial Statements).